Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cocrystal pleomorphism-inspired drug nanoassembly for pulmonary-endothelium targeting and pulmonary hypertension treatment.

Acta pharmaceutica Sinica. B·2025
Same author

Deep Eutectic Solvents for Essential-Oil Delivery and Bacterial-Infected Wound Healing.

Langmuir : the ACS journal of surfaces and colloids·2024
Same author

Injectable long-acting formulations (ILAFs) and manufacturing techniques.

Expert opinion on drug delivery·2024
Same author

Multifunctional nanoparticle-mediated combining therapy for human diseases.

Signal transduction and targeted therapy·2023
Same author

Pulmonary endothelium-targeted nanoassembly of indomethacin and superoxide dismutase relieves lung inflammation.

Acta pharmaceutica Sinica. B·2023
Same author

Drug Delivery and Therapy Strategies for Osteoporosis Intervention.

Molecules (Basel, Switzerland)·2023

Related Experiment Video

Updated: Oct 1, 2025

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

11.6K

Targeted Drug Delivery for Chronic Lymphocytic Leukemia.

Makhloufi Zoulikha1, Wei He2,3

  • 1Department of Pharmaceutics, School of Pharmacy, China Pharmaceutical University, Nanjing, 211198, China.

Pharmaceutical Research
|March 8, 2022
PubMed
Summary

Nanocarriers offer new hope for treating chronic lymphocytic leukemia (CLL), an incurable cancer. This review explores various nanocarrier types for improved drug delivery and targeting in CLL therapy.

Keywords:
ChemotherapyChronic lymphocytic leukemiaHematological diseasesNanomedicinesTargeted drug delivery

More Related Videos

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

7.7K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K

Related Experiment Videos

Last Updated: Oct 1, 2025

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking
11:39

Subcellular Fractionation of Primary Chronic Lymphocytic Leukemia Cells to Monitor Nuclear/Cytoplasmic Protein Trafficking

Published on: October 23, 2019

11.6K
Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

7.7K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K

Area of Science:

  • Oncology
  • Nanomedicine
  • Drug Delivery

Background:

  • Chronic lymphocytic leukemia (CLL) remains incurable despite advancements in characterization and therapy.
  • Existing treatments face challenges including progression to aggressive cancers and drug resistance.

Purpose of the Study:

  • To review nanocarrier systems for chronic lymphocytic leukemia (CLL) treatment.
  • To discuss features, targeting capabilities, and recent data on nanocarriers for CLL.
  • To provide a resource for designing nanomedicines against CLL.

Main Methods:

  • Literature review of nanocarrier applications in chronic lymphocytic leukemia (CLL).
  • Analysis of lipidic, polymeric, and inorganic nanocarrier types.
  • Discussion of targeting strategies and drug delivery improvements.

Main Results:

  • Various nanocarriers show potential for targeted delivery in CLL.
  • Nanocarriers can enhance the effectiveness and reduce toxicity of CLL drugs.
  • Different nanocarrier types offer unique advantages for CLL therapy.

Conclusions:

  • Nanocarriers represent a promising strategy to improve CLL treatment outcomes.
  • Rational design of nanomedicines is crucial for advancing CLL therapy.
  • Further research into nanocarrier drug delivery is essential for overcoming CLL challenges.